Drugs /

in10018

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of the non-receptor, cytoplasmic tyrosine kinase protein tyrosine kinase 2 (focal adhesion kinase 1; FAK1; FAK: PTK2) with potential antineoplastic activity. Upon oral administration, IN10018 targets and inhibits, in an adenosine triphosphate (ATP)-competitive manner, PTK2. This prevents PTK2-mediated downstream signaling and inhibits migration, proliferation, invasion, and survival in PTK2-overexpressing tumor cells. The cytoplasmic tyrosine kinase PTK2, a signal transducer for integrins overexpressed in various tumor cell types, is involved in tumor cell invasion, migration and proliferation.

Clinical Trials

View Clinical Trials for in10018

In10018 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating in10018, 1 is phase 1 (1 open).

NRAS Mutation is the most frequent biomarker inclusion criterion for in10018 clinical trials.

Melanoma and uveal melanoma are the most common diseases being investigated in in10018 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating In10018
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating in10018 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ptk2 inhibitor in10018, protein tyrosine kinase 2 inhibitor in10018, in-10018, in 10018, fak1 inhibitor in10018, bi853520, bi-853520, bi 853520
NCIT ID [1]:
C166122

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.